Results 1 to 10 of about 1,997 (174)

Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia [PDF]

European Journal of Medical Research
Background Lomitapide reduces plasma low-density lipoprotein cholesterol (LDL-C) and is approved for the treatment of homozygous familial hypercholesterolemia (HoFH).
Anouar Hafiane, Annalisa Ronca, Matteo Incerti, Alessandra Rossi, Matteo Manfredini, Elda Favari   +5 more
doaj   +4 more sources

New insights into the management of homozygous familial hypercholesterolemia patients treated with lomitapide: a single-center experience [PDF]

Frontiers in Endocrinology
Familial hypercholesterolemia (FH) is a genetic disease, usually with onset during childhood, characterized by elevated blood LDL cholesterol levels and potentially associated with severe cardiovascular complications. Concerning mutated genes in FH, such
Gabriella Iannuzzo, Ilenia Lorenza Calcaterra, Marco Gentile, Claudia Stanzione, Francesca de Ruberto, Maria Donata di Taranto, Giovanna Cardiero, Giuliana Fortunato, Matteo Di Minno   +8 more
doaj   +5 more sources

Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma [PDF]

JCI Insight
More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to ...
Alyona Ivanova, Taylor M. Wilson, Kimia Ghannad-Zadeh, Esmond Tse, Robert Flick, Megan Wu, Sunit Das   +6 more
doaj   +3 more sources

Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Homozygous Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Efficacy and Safety. [PDF]

Cardiovasc Drugs Ther
Homozygous Familial Hypercholesterolemia (HoFH) is a rare and life-threatening genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and early-onset atherosclerotic cardiovascular disease.
Nasser M, Mohammed HE, Haseeb ME, Darwish MK, Hanen G, Abdelaziz NA, Heiba AH, Shata A, Abdelkader MS.   +8 more
europepmc   +2 more sources

Lomitapide response in a cohort of patients with homozygous familial hypercholesterolemia and the potential influence of MTTP gene variants. [PDF]

Orphanet J Rare Dis
Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder of lipoprotein metabolism caused by pathogenic variants in both alleles of key low-density lipoprotein receptor (LDLR)-mediated pathway genes, resulting in very high LDL ...
Kolovou G, Kolovou V, Anagnostopoulou K, Anastasiou G, Kalogeropoulos P, Liberopoulos E.   +5 more
europepmc   +2 more sources

Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma [PDF]

Nature Communications
Cystine/cysteine is critical for antioxidant response and sulfur metabolism in cancer cells and is one of the most depleted amino acids in the microenvironment of pancreatic ductal adenocarcinoma (PDAC).
Yunzhan Li, Zekun Li, Qin Li, Dongxiao Sun, Bo Ni, Mingjun Tan, Ashley E. Shay, Min Wang, Chenyang Meng, Guangcong Shen, Boyang Fu, Yueying Shan, Shiqi Zhang, Rifah Rownak Tanshee, Tianxing Zhou, Yongjie Xie, Kun-Ming Chen, Bin Qiao, Yunkun Dang, Scot R. Kimball, Guanshi Zhang, Girish H. Rajacharya, Pankaj K. Singh, Xiuchao Wang, Jihui Hao, Shengyu Yang   +25 more
doaj   +2 more sources

Lomitapide: A Medication Use Evaluation and a Formulary Perspective [PDF]

Global Journal on Quality and Safety in Healthcare
Introduction Lomitapide is approved for lowering low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemia, which is a rare genetic disorder.
Laila Carolina Abu Esba, Hani Alharbi
doaj   +2 more sources

Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models

Cell Death Discovery, 2023
Palmitoylation of proteins plays important roles in various physiological processes, such as cell proliferation, inflammation, cell differentiation etc. However, inhibition of protein palmitoylation has led to few new drugs to date.
Yumeng Wang, Shujie Zhang, Huiqin He, Hongyi Luo, Yannan Xia, Yuanyuan Jiang, Jingwei Jiang, Li Sun   +7 more
doaj   +2 more sources

A real-world analysis of Lomitapide-associated adverse events: Data from FAERS and CVAROD. [PDF]

Medicine (Baltimore)
Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor approved for the treatment of Homozygous Familial Hypercholesterolemia (HoFH), effectively lowers LDL cholesterol but raises safety concerns, particularly regarding hepatic and ...
Liu X, Zheng Z, Chen Q, Liu Y, Li S, Wang H.   +5 more
europepmc   +2 more sources

Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation

MedComm – Oncology
Osimertinib resistance remains a significant challenge in the treatment of non‐small cell lung cancer (NSCLC). N6‐methyladenosine (m6A) modifications are closely linked to various mechanisms of anticancer resistance and autophagy, offering new avenues ...
Xiaohui Du, Congcong Zhang, Ying Li, Peipei He, Jian Wang, Xuena Chen, Han Wang, Qi Wang   +7 more
doaj   +2 more sources